47.27
price up icon3.62%   1.65
after-market After Hours: 46.55 -0.72 -1.52%
loading
Bridgebio Pharma Inc stock is traded at $47.27, with a volume of 2.82M. It is up +3.62% in the last 24 hours and up +9.47% over the past month. BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$45.62
Open:
$45.63
24h Volume:
2.82M
Relative Volume:
0.94
Market Cap:
$8.98B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-19.61
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+3.53%
1M Performance:
+9.47%
6M Performance:
+38.18%
1Y Performance:
+82.16%
1-Day Range:
Value
$45.55
$48.06
1-Week Range:
Value
$45.11
$48.06
52-Week Range:
Value
$21.72
$48.68

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Name
Bridgebio Pharma Inc
Name
Phone
(650) 391-9740
Name
Address
3160 PORTER DR., PALO ALTO, CA
Name
Employee
730
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
BBIO's Discussions on Twitter

Compare BBIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
47.27 8.66B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-30-25 Resumed Raymond James Outperform
Jul-21-25 Initiated Truist Buy
Jul-14-25 Initiated Jefferies Buy
Jul-09-25 Upgrade Oppenheimer Perform → Outperform
Jun-17-25 Initiated Wolfe Research Outperform
Mar-31-25 Initiated Redburn Atlantic Buy
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-03-24 Initiated Oppenheimer Perform
Sep-04-24 Initiated Piper Sandler Overweight
Mar-21-24 Resumed Raymond James Outperform
Jan-31-24 Initiated BMO Capital Markets Market Perform
Dec-08-23 Initiated Wells Fargo Overweight
Nov-07-23 Initiated Citigroup Buy
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Jul-18-23 Downgrade Jefferies Buy → Hold
Apr-19-23 Initiated Evercore ISI Outperform
Feb-06-23 Initiated Cowen Outperform
Dec-27-21 Reiterated Mizuho Buy
Dec-27-21 Reiterated SVB Leerink Outperform
Sep-10-21 Upgrade BofA Securities Neutral → Buy
May-21-21 Initiated UBS Buy
Mar-22-21 Reiterated Goldman Buy
Feb-22-21 Resumed JP Morgan Overweight
Feb-09-21 Resumed Goldman Buy
Jan-11-21 Reiterated H.C. Wainwright Buy
Dec-10-20 Reiterated H.C. Wainwright Buy
Jun-25-20 Initiated BofA/Merrill Neutral
May-19-20 Initiated BTIG Research Buy
Apr-13-20 Initiated H.C. Wainwright Buy
Feb-19-20 Initiated Mizuho Buy
Jul-26-19 Initiated Raymond James Outperform
Jul-22-19 Initiated BMO Capital Markets Outperform
Jul-22-19 Initiated Goldman Buy
Jul-22-19 Initiated JP Morgan Overweight
Jul-22-19 Initiated Jefferies Buy
Jul-22-19 Initiated Piper Jaffray Overweight
Jul-22-19 Initiated SVB Leerink Outperform
View All

Bridgebio Pharma Inc Stock (BBIO) Latest News

pulisher
Jul 31, 2025

Is it the right time to buy BridgeBio Pharma Inc. stockFinancial News Data Feed With Proven Results - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 30, 2025

BridgeBio Pharma Inc. stock volume spike explainedPotential Breakout Stock List Published This Week - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Raymond James assumes coverage on BridgeBio stock with Outperform rating - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

BridgeBio Pharma Inc. Breaks Losing Streak — Is the Trend ReversingEarly Entry Tips With Low Risk Zone Shared - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Cantor Fitzgerald maintains BridgeBio stock rating, sees $3B+ potential By Investing.com - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN

Jul 29, 2025
pulisher
Jul 28, 2025

BridgeBio Pharma Inc. Hits Oversold Level on RSI IndicatorEntry Alert Based on Volume Spikes Detected - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Is BridgeBio Pharma Inc. a growth stock or a value stockPre Market Forecasts Backed By Experts - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What makes BridgeBio Pharma Inc. stock price move sharplyEarly Breakout Entry Point Notifications Sent - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Moving Average Crossover Confirms Uptrend in BridgeBio Pharma Inc.Stock Screener With Smart Filters Highlights Top Picks - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-28 13:33:40 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Will BridgeBio Pharma Inc. stock benefit from interest rate changesWeekly Chart Analysis With Entry Advice Provided - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Why BridgeBio Pharma Inc. stock attracts strong analyst attentionLow Volatility Stable Growth Picks Rank High - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What are the latest earnings results for BridgeBio Pharma Inc.Triple-digit returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is BridgeBio Pharma Inc. stock compared to the marketRecord-breaking capital gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is BridgeBio Pharma Inc. company’s growth strategyFree Risk Assessment Services - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How many analysts rate BridgeBio Pharma Inc. as a “Buy”Unlock your trading potential today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 05:26:40 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about BridgeBio Pharma Inc. stockExplosive market performance - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Why BridgeBio Pharma Inc. stock is on top investor watchlistsMarket-leading growth rates - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives BridgeBio Pharma Inc. stock priceFree Stock Market Query - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Bridgebio Pharma shares rise 1.97% premarket after novel human genetics evidence confirms estimates of genetic prevalence and underdiagnosis of ADH1. - AInvest

Jul 24, 2025
pulisher
Jul 23, 2025

10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Groundbreaking Genetics Study Uncovers 25,000 Hidden ADH1 Cases in US and EU, Most Patients Undiagnosed - Stock Titan

Jul 23, 2025
pulisher
Jul 23, 2025

BridgeBio Pharma Inc. Stock Analysis and ForecastConsistently profitable trades - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is BridgeBio Pharma Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

BridgeBio Pharma, Inc. Scheduled to Release Q2 Financial Results and Business Updates on August 5, 2025 - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

BridgeBio, Genetic Disease Pioneer, Sets Q2 2025 Earnings Release DateKey Details Inside - Stock Titan

Jul 22, 2025
pulisher
Jul 21, 2025

Truist Securities Initiates Coverage on BridgeBio Pharma with 'Buy' Rating and $66 Price Target - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio Pharma Stock (BBIO) Opinions on Analyst Buy Ratings and Attruby Launch - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Se - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Securities | BBIO Stock News - GuruFocus

Jul 21, 2025

Bridgebio Pharma Inc Stock (BBIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):